PE20250022A1 - Inhibidores de alk2 quinasa que contienen imidazol - Google Patents

Inhibidores de alk2 quinasa que contienen imidazol

Info

Publication number
PE20250022A1
PE20250022A1 PE2023003085A PE2023003085A PE20250022A1 PE 20250022 A1 PE20250022 A1 PE 20250022A1 PE 2023003085 A PE2023003085 A PE 2023003085A PE 2023003085 A PE2023003085 A PE 2023003085A PE 20250022 A1 PE20250022 A1 PE 20250022A1
Authority
PE
Peru
Prior art keywords
alkyl
formula
ring
compounds
kinase inhibitors
Prior art date
Application number
PE2023003085A
Other languages
English (en)
Spanish (es)
Inventor
Pravin L Kotian
Yarlagadda S Babu
Weihe Zhang
Wei Lv
peng-cheng Lu
Andrew E Spaulding
Krishnan Raman
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PE20250022A1 publication Critical patent/PE20250022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2023003085A 2021-05-25 2022-05-24 Inhibidores de alk2 quinasa que contienen imidazol PE20250022A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192822P 2021-05-25 2021-05-25
PCT/US2022/030690 WO2022251188A2 (en) 2021-05-25 2022-05-24 Imidazole-containing inhibitors of alk2 kinase

Publications (1)

Publication Number Publication Date
PE20250022A1 true PE20250022A1 (es) 2025-01-07

Family

ID=84230377

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003085A PE20250022A1 (es) 2021-05-25 2022-05-24 Inhibidores de alk2 quinasa que contienen imidazol

Country Status (23)

Country Link
US (1) US20240270750A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346806A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520359A (cg-RX-API-DMAC7.html)
KR (1) KR20240013145A (cg-RX-API-DMAC7.html)
CN (1) CN117529315A (cg-RX-API-DMAC7.html)
AR (1) AR125963A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022283258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024537A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219966A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003503A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230597A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000254A (cg-RX-API-DMAC7.html)
EC (1) ECSP23096182A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416425A (cg-RX-API-DMAC7.html)
IL (1) IL308513A (cg-RX-API-DMAC7.html)
JO (1) JOP20230303A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013742A (cg-RX-API-DMAC7.html)
PE (1) PE20250022A1 (cg-RX-API-DMAC7.html)
PY (1) PY2240952A (cg-RX-API-DMAC7.html)
TW (1) TW202313625A (cg-RX-API-DMAC7.html)
UY (1) UY39788A (cg-RX-API-DMAC7.html)
WO (1) WO2022251188A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
BR0111754A (pt) * 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
JP2012504157A (ja) * 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CN108239071B (zh) * 2016-12-27 2020-12-04 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見

Also Published As

Publication number Publication date
BR112023024537A2 (pt) 2024-02-06
UY39788A (es) 2023-01-31
JP2024520359A (ja) 2024-05-24
IL308513A (en) 2024-01-01
PY2240952A (es) 2022-12-26
EP4346806A2 (en) 2024-04-10
DOP2023000254A (es) 2023-12-29
US20240270750A1 (en) 2024-08-15
CA3219966A1 (en) 2022-12-01
AR125963A1 (es) 2023-08-30
ECSP23096182A (es) 2024-01-31
JOP20230303A1 (ar) 2023-11-23
MX2023013742A (es) 2023-11-28
WO2022251188A3 (en) 2023-01-05
AU2022283258A1 (en) 2024-01-04
KR20240013145A (ko) 2024-01-30
CR20230597A (es) 2024-02-20
CL2023003503A1 (es) 2024-05-03
WO2022251188A8 (en) 2024-01-04
WO2022251188A2 (en) 2022-12-01
CO2023017975A2 (es) 2024-01-15
EP4346806A4 (en) 2025-07-23
CN117529315A (zh) 2024-02-06
TW202313625A (zh) 2023-04-01
GEAP202416425A (en) 2024-02-12

Similar Documents

Publication Publication Date Title
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
PE20252338A1 (es) Compuesto agonista de receptor thrb y metodo de preparacion
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20200445A1 (es) Inhibidores pirazolicos de magl
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR127704A1 (es) Derivados de piridazina inhibidores de nlrp3
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
AR124199A1 (es) Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
MY143245A (en) 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa